Alto Neuroscience vs ImmunoVec
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patients to drugs using brain biology. 4 data readouts through 2027.
About
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral delivery for CAR-T-like therapies.
About
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.